OPR - Delayed Quote • USD BIIB May 2024 230.000 call (BIIB240503C00230000) Follow 1.9600 0.0000 (0.00%) At close: April 23 at 3:28 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for BIIB240503C00230000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: BIIB Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals Decoding Biogen Inc (BIIB): A Strategic SWOT Insight Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients? Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do Q1 2024 Biogen Inc Earnings Call Why Biogen Stock Leaped Nearly 5% Higher Today Biogen Stock Surges After Two Notable Products Walloped Sales Expectations
